CagriSema FDA Approval Status July 2026

Scope note: This approval tracker covers evidence and regulatory timing only. It does not cover pharmacy access, pricing, or research-supply listings. For broader context, use the approval trackers hub and the CagriSema profile.

What Is CagriSema and How Does It Work?

CagriSema is Novo Nordisk’s investigational once-weekly subcutaneous injection that combines two active compounds in a single prefilled pen: cagrilintide 2.4 mg, a long-acting amylin analog, and semaglutide 2.4 mg, a GLP-1 receptor agonist (the same active ingredient in Wegovy).

The rationale behind the combination is targeting two distinct hormonal pathways involved in appetite regulation and energy balance. Semaglutide activates GLP-1 receptors to reduce appetite and food intake — a well-established mechanism used in Wegovy and Ozempic. Cagrilintide mimics the hormone amylin, which is naturally co-secreted with insulin from pancreatic beta cells after meals. Amylin signaling promotes satiety, slows gastric emptying, and suppresses glucagon secretion. For a deeper look at this dual-pathway mechanism, see our CagriSema amylin and GLP-1 research profile.

By combining both pathways, CagriSema aims to produce greater weight loss than either component alone. The REDEFINE 1 trial data support this hypothesis — the combination outperformed semaglutide monotherapy by a clinically meaningful margin.

Once Weekly CagriSema: First-in-Class Combination Pharmacology

Once weekly CagriSema represents the first once weekly combination of a long acting amylin analogue with a GLP-1 receptor agonist. The underlying pharmacology centres on engaging two complementary satiety pathways simultaneously. Cagrilintide and semaglutide each act through distinct receptor systems — amylin receptors in the area postrema and GLP-1 receptors in the hypothalamus — creating a novel mechanism that produces additive effects on appetite suppression.

This amylin analogue combination approach is what makes once weekly CagriSema a first-in-class combination in the obesity pharmacotherapy space. Public Novo Nordisk materials cited on this page continue to describe CagriSema as a fixed-dose combination of cagrilintide and semaglutide while the obesity filing remains under FDA review. The long-acting amylin analogue component (cagrilintide) has an extended half-life engineered through acylation technology, enabling once-weekly dosing rather than the multiple daily injections required by native amylin. Participants treated with CagriSema across the REDEFINE programme consistently demonstrated greater body-weight reduction than those treated with either component alone, supporting the rationale for the cagrilintide and semaglutide combination.

What Is CagriSema FDA Approval Status in 2026?

No — CagriSema is not FDA approved in 2026 as of July 4, 2026. Novo Nordisk filed a New Drug Application (NDA) with the FDA on December 18, 2025, seeking approval of CagriSema for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The filing was based on the REDEFINE Phase 3 clinical program.

Novo Nordisk's Q1 2026 investor materials point to a Q4 2026 U.S. decision window for the obesity submission. No exact PDUFA (Prescription Drug User Fee Act) target date has been publicly confirmed as of July 4, 2026. Track every pending decision on our obesity drug approval tracker for 2026.

The REDEFINE-4 readout in February 2026 missed the non-inferiority margin against tirzepatide 15 mg, but the NDA pre-dates that data and rests on placebo-controlled REDEFINE-1. The FDA evaluates total evidence of safety and efficacy versus placebo, so a head-to-head miss against a competitor does not, by itself, block approval. REIMAGINE (T2D, Feb 2026) also reported CagriSema outperforming semaglutide.

CagriSema has not received approval from any regulatory agency worldwide. The European Medicines Agency (EMA) review status has not been publicly disclosed.

Other 2026 Watch Points Around the Review

Public 2026 reporting has covered more than the headline FDA timing. In February, Novo disclosed the REDEFINE-4 head-to-head result versus tirzepatide, and in May outside reporting discussed possible changes to the eventual delivery configuration. Those updates matter for launch planning and investor expectations, but they do not change the regulatory bottom line on this page: CagriSema remains under FDA review, with no public PDUFA date posted.

The core evidence package remains the same: cagrilintide plus semaglutide, once weekly, supported by placebo-controlled REDEFINE data. Commercial presentation details may still evolve during review and launch planning, whereas the current FDA answer is still governed by the submitted clinical dossier and Novo’s public timing guidance.

ECO 2026 body composition (May 2026, Türkiye). A REDEFINE-1 sub-analysis presented at the European Congress on Obesity reported a muscle-sparing weight loss profile for CagriSema — lean-mass preservation relative to total weight loss is increasingly a focus point across the GLP-1 class. See the Pharmaceutical Technology analyst comment.

FDA Submission Details and Regulatory Pathway

The CagriSema FDA submission was filed on December 18, 2025, and reflects the totality of evidence from the REDEFINE clinical programme. The application included data from multiple Phase 3 trials encompassing thousands of trial participants across different populations — with REDEFINE-1 as the placebo-controlled primary efficacy dataset (22.7% weight loss at 68 weeks). Because the filing pre-dates the REDEFINE-4 February 2026 readout, the head-to-head miss against tirzepatide does not undercut the application’s evidentiary basis; the FDA review is driven by placebo-controlled efficacy and safety, not comparator positioning.

The CagriSema application is being reviewed under the standard pathway, and any advisory committee meetings would be scheduled during the review period. If approval lands in the current Q4 2026 guidance window, launch-format questions may still sit alongside reimbursement and manufacturing decisions, but none of those commercial details change the current approval answer.

What Did the REDEFINE Trials Show?

The REDEFINE clinical program is a series of Phase 3 trials evaluating CagriSema across different patient populations and treatment scenarios. The headline results from the key trials:

REDEFINE 1 (obesity, primary trial): CagriSema demonstrated 22.7% mean body weight loss at 68 weeks, compared to 16.0% for semaglutide 2.4 mg alone and 1.8% for placebo. This was a head-to-head comparison with the active ingredient in Wegovy, and the 6.7 percentage-point difference was statistically significant. Results were published in The Lancet in 2024.

REIMAGINE (type 2 diabetes, Feb 2026): In adults with type 2 diabetes, CagriSema outperformed semaglutide, with a superior HbA1c reduction (1.91 points) and 14.2% weight loss. Weight loss in people with type 2 diabetes is typically lower than in non-diabetic populations across all obesity drugs, so a T2D head-to-head win against the standard-of-care GLP-1 is a meaningful result for the combination. See Novo Nordisk's REIMAGINE disclosure.

REDEFINE 3 (maintenance after semaglutide lead-in): This trial evaluated CagriSema as a step-up therapy in patients who had already lost weight on semaglutide. Results showed further weight loss with CagriSema versus placebo after the semaglutide lead-in period, supporting the combination as an escalation option.

REDEFINE 4 (head-to-head vs tirzepatide, February 2026): In 809 participants with obesity and at least one weight-related comorbidity, CagriSema achieved 20.2% mean weight loss at 84 weeks (treatment-regimen estimate) versus 23.6% for tirzepatide 15 mg. On-treatment estimates were 23.0% and 25.5%, respectively. CagriSema failed to meet the primary endpoint of non-inferiority to tirzepatide. The trial was open-label. Both drugs were well-tolerated with similar GI side-effect profiles. See our full REDEFINE 4 breakdown.

REDEFINE 6 (adolescents 12–17): This trial in adolescents aged 12 to 17 is ongoing. Results have not yet been reported.

Clinical Efficacy: Body Weight Reduction and Primary Endpoints

The primary endpoint of the REDEFINE 1 trial was percentage body weight reduction from baseline at 68 weeks. Participants taking CagriSema achieved superior weight loss compared with the placebo group and the semaglutide monotherapy arm. The treatment effect size for body weight reduction was clinically meaningful, with consistent efficacy demonstrated across all pre-specified subgroups. Weight reduction of 22.7% represents substantial capacity to reduce excess body weight in adults living with either obesity or overweight with one or more comorbidities.

Placebo Group and Treatment Effect Size

In the placebo controlled REDEFINE 1 trial, the placebo group achieved only 1.8% weight reduction at 68 weeks, confirming that the treatment effect observed with once weekly CagriSema was attributable to the active compound rather than lifestyle intervention alone. All trial participants, including the placebo group, received counselling on reduced calorie diet and increased physical activity as part of standard background care. The average baseline body weight across the study population was consistent with other late stage trials in obesity, and the higher dose of semaglutide (2.4 mg) used in the active comparator arm set a high bar for demonstrating the weight loss potential of the combination. Supportive secondary analysis confirmed that weight reduction long term was maintained through week 68 in participants taking CagriSema achieved targets, with body weight reduction increasing progressively through the treatment period. Excess body weight decreased substantially across all active treatment groups.

Trial Participants and Completion Rates

The REDEFINE programme enrolled trial participants with either obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight related comorbid condition such as type 2 diabetes, hypertension, or dyslipidemia. High treatment completion rates were observed across all REDEFINE trials, with the vast majority of patients who started treatment completing the full 68-week period. Patients stayed on therapy at rates comparable to or better than other placebo controlled obesity trials, reflecting the tolerability profile consistent with prior Phase 2 data. The most common adverse events were gastrointestinal—nausea, diarrhea, and vomiting—and these common adverse events occurred primarily during the dose-escalation phase. Patient relevant outcomes, including quality-of-life measures and physical function, were assessed as secondary endpoints.

CagriSema vs Incretin Agonists

CagriSema occupies a mechanistically distinct position from the incretin-based agonists dominating the obesity pipeline. Tirzepatide (GLP-1/GIP dual agonist) and retatrutide (GLP-1/GIP/GCGR triple agonist) both operate within the incretin receptor superfamily, stacking overlapping downstream signaling cascades — GLP-1R and GIPR share cAMP-dependent pathways, and GCGR adds energy expenditure via hepatic signaling. Remy Peptides supplies a research-grade retatrutide pen, COA-verified by Janoshik, for laboratory use in Dubai. CagriSema takes a fundamentally different approach: it pairs semaglutide’s GLP-1 receptor activation with cagrilintide’s engagement of the amylin receptor system, targeting two non-overlapping satiety pathways.

The receptor pharmacology distinction is significant. Incretin-based combinations target receptors from the same family — GLP-1R, GIPR, and GCGR are all class B1 G-protein-coupled receptors that share structural homology and downstream signaling elements. CagriSema’s amylin component acts through an entirely different receptor system: calcitonin receptor (CALCR) complexed with receptor activity-modifying proteins (RAMPs). Amylin signals primarily through the area postrema, a circumventricular organ outside the blood-brain barrier, while GLP-1 acts on hypothalamic appetite circuits and brainstem GLP-1 receptors. This means CagriSema engages satiety circuitry in brain regions that incretin-only combinations do not directly reach.

In clinical terms, the REDEFINE 4 head-to-head trial showed tirzepatide outperforming CagriSema on the primary weight-loss endpoint (23.6% vs 20.2% at 84 weeks). However, the non-overlapping pathway rationale remains valuable for research — specific metabolic subpopulations where incretin resistance or amylin-pathway deficiency limits GLP-1/GIP efficacy may respond differently to amylin-based combination strategies. The mechanistic breakdown above covers the full amylin and GLP-1 research profile for CagriSema.

CagriSema in the Amylin Landscape

CagriSema is not the only compound advancing the amylin thesis. Petrelintide, a standalone long-acting amylin analog developed by Roche and Zealand Pharma, reported Phase 2 results (ZUPREME-1) in March 2026 with a compelling profile: 10.7% weight loss at 42 weeks and a “placebo-like” GI tolerability profile — including zero vomiting cases in the highest dose group and zero discontinuations due to gastrointestinal adverse events. For a full compound breakdown, see our petrelintide research profile.

On headline weight-loss numbers, CagriSema leads significantly: 22.7% versus petrelintide’s 10.7%. But direct comparison requires caution — these figures come from different trial designs, different patient populations, and different durations (REDEFINE 1 at 68 weeks vs ZUPREME-1 at 42 weeks). CagriSema’s higher efficacy is expected given that it combines two active mechanisms (amylin + GLP-1), while petrelintide targets only the amylin pathway as a monotherapy. The more relevant question is not which produces more weight loss in isolation, but how each positions within the broader treatment landscape.

Petrelintide’s exceptional tolerability raises a strategic question for the amylin field: could a standalone amylin analog with minimal GI burden serve as an add-on therapy to existing GLP-1 regimens? GI side effects are the primary reason patients discontinue GLP-1-based treatments, and a drug that delivers meaningful weight loss without compounding the side-effect load becomes an attractive combination partner. Petrelintide could theoretically be layered on top of semaglutide, tirzepatide, or retatrutide — providing amylin-pathway benefit that CagriSema bundles in a fixed dose but that standalone amylin analogs could deliver more flexibly. For a detailed head-to-head analysis, see our petrelintide vs CagriSema comparison.

What Are the Side Effects of CagriSema?

The side-effect profile of CagriSema in the REDEFINE trials was broadly consistent with the known effects of GLP-1 receptor agonists. The most commonly reported adverse events were gastrointestinal: nausea, vomiting, and diarrhea. These GI side effects were generally mild to moderate and most common during the dose-escalation phase.

In REDEFINE 1, the overall rate of GI adverse events was slightly higher with CagriSema than with semaglutide 2.4 mg alone. This is expected given that the combination adds cagrilintide — which slows gastric emptying through amylin signaling — on top of semaglutide’s GLP-1-mediated effects on gastric motility.

Treatment discontinuation due to adverse events was reported, but the overall tolerability profile did not raise new safety signals beyond what is known for the individual components. The full safety dataset from the REDEFINE program is part of the NDA currently under FDA review. For context on where CagriSema fits among other investigational compounds, see our obesity drug approval tracker.

What Happens Next?

Four developments define the near-term trajectory for CagriSema:

1. FDA review decision (Q4 2026 guidance). The NDA filed December 18, 2025 is under review. Novo Nordisk's current investor materials point to a Q4 2026 U.S. decision window, and no exact PDUFA date has been publicly confirmed. Any advisory committee meetings or FDA information requests would be announced publicly.

2. Launch-format planning. Public reporting has suggested delivery-format decisions may keep evolving during launch planning. That matters operationally, but it remains secondary to the FDA review outcome and any eventual label details.

3. REDEFINE 6 (adolescent data). The ongoing trial in adolescents aged 12–17 will expand the dataset to younger populations. Pediatric obesity data has become increasingly important for regulatory and market positioning, as seen with tirzepatide and semaglutide pediatric trials.

4. Competitive landscape. CagriSema enters a market where tirzepatide (Zepbound) is already approved with comparable weight-loss figures (22.5% in SURMOUNT-1) and outperformed CagriSema in the only head-to-head trial (REDEFINE-4: 23.6% vs 20.2% at 84 weeks). Competitive positioning depends on the amylin–GLP-1 mechanism, the ECO 2026 muscle-sparing signal, and whether the FDA views the current package as differentiated enough for approval. Retatrutide (Eli Lilly’s triple-agonist, Phase 3) and survodutide (Boehringer Ingelheim’s dual GLP-1/glucagon agonist, Phase 3) are also advancing. See our retatrutide vs tirzepatide vs CagriSema comparison for a full breakdown.

Novo Nordisk’s Obesity Pipeline and Market Outlook

Novo Nordisk’s obesity pipeline extends well beyond CagriSema. The company’s portfolio includes semaglutide (Wegovy), which already commands significant market share in the GLP-1 obesity category, and amycretin, a next-generation unimolecular GLP-1/amylin agonist in Phase 2 development. If approved, CagriSema would expand treatment options for healthcare professionals managing patients with obesity and provide patients with an additional treatment option supported by well-powered Phase 3 data. Novo Nordisk’s obesity pipeline is the deepest among pharmaceutical companies, with multiple late stage trial programmes addressing different patient segments.

Addressing Unmet Medical Needs in Obesity Care

The approval of CagriSema would address unmet medical needs in obesity care by providing a novel mechanism distinct from existing GLP-1-only and GLP-1/GIP dual agonist therapies. Healthcare professionals increasingly recognise that treatment options for obesity must account for metabolic disease, obesity related complications, and the broader cardiometabolic burden associated with excess body weight. CagriSema’s dual pathway approach could provide patients with a holistic treatment strategy that targets both appetite regulation and metabolic dysfunction. Event driven cardiovascular outcomes trials for obesity drugs—including the SELECT trial with semaglutide—have demonstrated that meaningful body weight reduction reduces cardiovascular risk, setting a precedent for the class. Non obesity indications, including type 2 diabetes management and potential benefits for metabolic disease comorbidities, represent additional opportunities to expand treatment options and grow market share. As the higher dose formulations of existing therapies face competition, the cagrilintide and semaglutide combination aims to offer unmet medical needs coverage that single-agent therapies cannot match.